Thursday, 17 Oct 2019

You are here

FINCH2: Filgotinib in Biologic Refractory Rheumatoid Arthritis

The FINCH2 study has shown that filgotinib, an oral once daily JAK 1 inhibitor, is highly effective in rheumatoid arthritis (RA) patients who failed to respond to prior biologic therapy.

A total of 448 active RA patients were enrolled in a 24 week trial if they had an inadequate response or intolerance to 1 or more biologic disease-modifying antirheumatic drugs, were maintained on their background conventional synthetic DMARDs (csDMARDs). Patients were randomized to either daily filgotinib, 200 mg (n = 148); filgotinib, 100 mg (n = 153); or placebo (n = 148). The primary endpoint was an ACR20 response at week 12. 

Week 12 outcomes showed filgotinib (FIL) to be significantly superior to placebo, with ACR20 responses:

  • FIL 200 mg = 66.0%
  • FIL 100 mg = 57.5%
  • PBO = 31.1%; (both P < .001),

Even in patients who failed 3 or more prior biologic agents, significant ACR20 responses were achieved with FIL 200 mg (70.3%) and FIL 100 mg (58.8%) compared with PBO treated patients (17.6%).

Common adverse events (in 5-10%) included nasopharyngitis, headache, and upper respiratory infections.

There were 4 cases of herpes zoster cases, 1 retinal vein occlusion and no reports of tuberculosis, opportunistic infections, malignancies, gastrointestinal perforations, or deaths.

This is one of the pivotal drug development trials for filgotinib in RA. Gilead is partnering with Galapagos in developing filgotinib for use in RA and is planning to file for FDA approval later this year.


The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Biologics Lead the Way in Drug Price Increases

Reuters has reported the results of a recent Institute for Clinical and Economic Review (ICER) analysis showing that biologics, especially Humira and Rituxan, are leading the way in the cost of drugs in the USA. All told, Humira and Rituxan topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. drug spending. ICER said their analysis points to price hikes that were more than twice the rate of medical inflation and were not warranted by any new clinical evidence.

Ustekinumab Efficacy in Ulcerative Colitis

The NEJM reports the results of a one year trial wherein ustekinumab (UST) was shown to be effective at inducing and maintaining remission in patients with moderate-to-severe ulcerative colitis. Ustekinumab, currently approved for use in psoriasis, psoriatic arthritis and Crohn's disease, is a monoclonal antibody against the p40 subunit of interleukin-12 and interleukin-23.

FDA Approves Rituximab for Children with GPA

The U.S. Food and Drug Administration has approved Rituxan (rituximab) for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children 2 years of age and older in combination with glucocorticoids. This is the first approved treatment for children with vasculitis.

Anakinra Shows Benefits in Cytokine Storm

The interleukin (IL)-1 receptor antagonist anakinra (Kineret) showed promise in critically ill children who develop the often-lethal condition known as secondary hemophagocytic lymphohistiocytosis (sHLH)/macrophage activation syndrome (MAS), a retrospective single-center study found.


Prior Authorizations Delay Care in Rheumatology

Physicians who believe their patients' health is negatively affected by insurers' demands for prior authorization, and the delays that often result, will find that opinion vindicated by a new study of rheumatology care: when permission had to be sought from insurers to provide intravenous drugs, average time to begin treatment was longer and patients had twice the corticosteroid exposure, a single-center analysis found.